U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07251491) titled 'Psilocybin to Treat Depression in Spinal Cord Injury' on Sept. 30.
Brief Summary: The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg).
The main question the study aims to answer is: does psilocybin increase the number and severity of adverse (bad) events reported by people with SCI? These may include pain, muscle spasms, symptoms of depression, and symptoms of low or high blood pressure. The investigators will also measure how well people with SCI tolerate the psychedelic ...